Reassessing patents in fighting COVID-19

Joseph E. Stiglitz, Arjun Jayadev and Achal Prabhala

IMAGINE a world in which a global network of medical professionals monitored for emerging strains of a contagious virus, periodically updated an established formula for vaccinating against it and then made that information available to companies and countries around the world. Moreover, imagine if this work were done without any intellectual-property considerations and without pharmaceutical monopolies exploiting a desperate public to maximize their profits.

This may sound like a utopian fantasy, but it is actually a description of how the flu vaccine has been produced for the past 50 years. Through the World Health Organization’s Global Influenza Surveillance and Response System, experts from around the world convene twice a year to analyze and discuss the latest data on emerging flu strains and to decide which strains should be included in each year’s vaccine. As a network of laboratories spanning more than 100 countries and regions, funded almost entirely by governments (and partly by foundations), GISRS epitomizes what Amy Kapczynski of Yale Law School calls “open science.”

Because GISRS is focused on protecting human lives rather than turning a profit, it is uniquely capable of gathering, interpreting and distributing actionable knowledge for the development of vaccines. While this approach may have been taken for granted in the past, its advantages are becoming clear.

In responding to the pandemic, the global scientific community has shown a remarkable willingness to share knowledge of potential treatments, coordinate clinical trials, develop new models transparently and publish findings immediately. In this new climate of cooperation, it is easy to forget that commercial pharmaceutical companies have for decades been privatizing and locking up the knowledge commons by extending control over life-saving drugs through unwarranted, frivolous or secondary patents, and by lobbying against the approval and production of generics.

With the arrival of COVID-19, it is now painfully obvious that such monopolization comes at the cost of human lives. Monopoly control over the technology used in testing for the virus has hampered the rapid rollout of more testing kits. Worse, multiple patents are in force in most of the world for three of the most promising treatments for COVID-19. Already, these patents are preventing competition and threatening both the affordability and the supply of new drugs.

We now have a choice between two futures. In the first scenario, we continue as usual, relying on the big pharmaceutical companies, hoping that some potential treatment for COVID-19 will make it through clinical trials, and that other technologies for detection, testing and protection will emerge. In this future, patents will give monopoly suppliers control over most of these innovations. The suppliers will set the price high, forcing downstream rationing of care. In the absence of strong public intervention, lives will be lost, particularly in developing countries.

The same problem will also apply to any potential COVID-19 vaccine. Unlike Jonas Salk’s polio vaccine, which was made freely available immediately, most vaccines that come to market today are patented. For example, PCV13, the current multi-strain pneumonia vaccine administered to babies, costs hundreds of dollars because it is the monopoly property of Pfizer.

In the second possible future, we would acknowledge that the current system — in which private monopolies profit from knowledge that is largely produced by public institutions — is not fit for purpose.

As public-health advocates and scholars have long argued, monopolies kill, by denying access to life-saving medicines that otherwise would have been available under an alternative system — like the one facilitating the yearly production of the flu vaccine.

Patent pooling

There is already some movement in favor of alternative approaches. For example, Costa Rica’s government recently called on the WHO to establish a voluntary pool of IP rights for COVID-19 treatments, which would allow multiple manufacturers to supply new drugs and diagnostics at more affordable prices.

Patent pooling is not a new idea. Through the Medicines Patent Pool, the United Nations and the WHO have for years sought to increase access to treatments for HIV/AIDS, hepatitis C and tuberculosis, and have now expanded that program to cover COVID-19. Patent pools, prize funds and other similar ideas are part of a broader agenda to reform how life-saving drugs are developed and made available.

The goal is to replace a monopoly-driven system with one based on cooperation and shared knowledge.

To be sure, some will argue that the

COVID-19 crisis is sui generis, or that the threat of compulsory licenses offers sufficient means for pressuring drug companies to behave well. But, beyond front-line researchers who are not motivated solely by short-term profits, it is not clear that the big pharmaceutical companies understand their responsibilities. After all, Gilead, the maker of remdesivir, one of the most promising treatments for COVID-19, initially reacted to the current crisis by applying for “orphan drug” status, which would have granted it a stronger monopoly position and multimillion-dollar tax breaks. (Following a public outcry, the company withdrew its application.)

For too long, we have bought into the myth that today’s IP regime is necessary. The proven success of GISRS and other applications of “open science” shows that it is not. With the COVID-19 death toll rising, we should question the wisdom and morality of a system that silently condemns millions of human beings to suffering and death every year.

It’s time for a new approach. Academics and policymakers have already come forward with many promising proposals for generating socially useful — rather than merely profitable — pharmaceutical innovation. There has never been a better time to start putting these ideas into practice.

Joseph E. Stiglitz is a Nobel laureate in economics and professor at Columbia University. Arjun Jayadev is professor of economics at Azim Premji University and senior economist at the Institute for New Economic Thinking. Achal Prabhala is a fellow at the Shuttleworth Foundation and coordinator of the accessibsa project. Copyright: Project Syndicate, 2020. www.project-syndicate.org